Description

Adefovir Dipivoxil is an acyclic nucleotide analog prodrug of adefovir, functioning as a reverse transcriptase inhibitor—widely used in hepatitis B research. Each tablet delivers 10?mg of active compound. Manufactured by Chia?Tian Chongxin Pharmaceutical (Dinghe), approved under NMPA registration number H20080034, with drug code 86904127003695 and barcode 6937861350224.

Ideal for in vitro or in vivo studies of antiviral mechanisms, viral drug resistance, and nucleoside analog pharmacodynamics. Not for clinical, diagnostic, or veterinary use—research use only.

Adefovir Dipivoxil Tablets Product Specifications

Adefovir Dipivoxil Tablets Mechanism & Research Applications

Adefovir Dipivoxil is a prodrug converted intracellularly to adefovir diphosphate, which inhibits hepatitis B virus polymerase by competing with natural deoxyadenosine triphosphate, causing DNA chain termination. It’s used extensively in research to study:

• HBV inhibition and viral replication kinetics

• Drug-resistance mutations and antiviral resilience

• Combination therapies and HBV polymerase function

• Pharmacokinetic and pharmacodynamic profiling in preclinical models

Adefovir Dipivoxil Tablets Safety & Handling

• Use: Strictly for laboratory research; not for human or veterinary administration

• Storage: Keep sealed and store below 30?°C

• Handling: Use PPE—lab coat, gloves, safety glasses

• Disposal: Follow institutional hazardous waste protocols

Core Keywords

Adefovir dipivoxil tablets, Dinghe antiviral tablet, 10?mg adefovir dipivoxil, HBV research compound, nucleotide analog for lab use, NMPA H20080034 adefovir, Chongxin adefovir dipivoxil, bulk antiviral research tablet, lab-grade reverse transcriptase inhibitor, hepatitis B prodrug research

Research Use Disclaimer

This product is exclusively for laboratory research use and is not approved for clinical, therapeutic, diagnostic, or veterinary purposes. Improper use may pose health risks. Always adhere to institutional biosafety and local regulations.